Q0138 HCPCS code: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
Q0138 is the HCPCS Level II code for injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use). In 2024 Medicare paid an average of $0.27 per service for Q0138 across 33,848,571 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 510 per day on outpatient hospital claims. Medicare volume fell 39% from 2022 to 2024 (55,131,698 to 33,848,571 services). In 2024, about 3,697 clinicians billed Medicare for Q0138 for 26,679 beneficiaries; Florida, Texas, California accounted for 54% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2010-01-01 |
| Last action effective | 2010-01-01 |
Who bills Q0138 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 3,697 |
| Medicare beneficiaries | 26,679 |
| States with claims | 46 |
| Share of services in top 3 states (Florida, Texas, California) | 54% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q0138, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 55,131,698 | 42,784 | $0.81 | $0.64 |
| 2023 | 43,875,794 | 34,208 | $0.50 | $0.39 |
| 2024 | 33,848,571 | 26,679 | $0.35 | $0.27 |
States with the most Q0138 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 10,753,913 | $0.28 |
| Texas | 4,855,910 | $0.27 |
| California | 2,702,019 | $0.27 |
| Illinois | 1,688,763 | $0.27 |
| Maryland | 1,492,260 | $0.27 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 510 | Prescribing Information |
| practitioner claims | 510 | Prescribing Information |
What changed for Q0138
- 2010-01-01: Q0138 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q0138?
Q0138 is the HCPCS Level II code for injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use). Short descriptor: "Ferumoxytol, non-esrd".
How much does Medicare pay for Q0138?
In 2024, the average Medicare payment was $0.27 per service (average allowed $0.35).
Does Medicare cover Q0138?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of Q0138 can be billed per day?
510 on outpatient hospital claims; 510 on practitioner claims (NCCI medically unlikely edits).
Related Q01 codes
- Q0111 — Wet mounts, including preparations of vaginal, cervical or skin specimens
- Q0112 — All potassium hydroxide (koh) preparations
- Q0113 — Pinworm examinations
- Q0114 — Fern test
- Q0115 — Post-coital direct, qualitative examinations of vaginal or cervical mucous
- Q0139 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
- Q0144 — Azithromycin dihydrate, oral, capsules/powder, 1 gram
- Q0155 — Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0161 — Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
- Q0164 — Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q0138
- Watch Q0138 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q0138
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.